Its roles Owner Operator
Genentech, Inc. is a U.S.-based biotechnology company and member of the Roche Group, focused on the discovery, development, and manufacture of biologic medicines. Founded in 1976 and headquartered in South San Francisco, California, the company is known for early contributions to recombinant DNA technology and monoclonal antibody therapeutics.
Genentech’s portfolio and pipeline span oncology, immunology, neuroscience, ophthalmology, hematology, and infectious diseases. The company operates integrated R&D and cGMP biomanufacturing across multiple sites, with capabilities in large-scale mammalian cell culture, purification, and sterile fill-finish, supported by process development, analytical sciences, and quality operations. Within Roche’s global network, Genentech manages clinical and commercial supply of several biologics, including bevacizumab, trastuzumab, rituximab (with partners), atezolizumab, ocrelizumab, tocilizumab, omalizumab, and ranibizumab. The company emphasizes advanced bioprocessing, automation, and data-driven manufacturing to support reliable supply and regulatory compliance.
chemXplore tracks 3 projects involving Genentech, of which 2 are active.
Besides these 2, the record holds 1 completed project.
Closest to start-up first.
The 1 that is completed, on hold or cancelled are in the record. See all 3 in chemXplore →
Phase III Krascendo 1: divarasib reduced risk of progression/death by 42% and risk of death by 44%; median OS ~17.7 vs 12.0 months; ORR 58% vs 32%; manageable safety.
Group sales +6% (CER) in first nine months; Q3 +7% (CER)/+8% CHF. Pharmaceuticals drove growth, diagnostics up despite China pricing reforms. 2026 outlook confirmed.
Phase III fenebrutinib data show reduced chronic active MS lesions and a 55% ARR cut; Ocrevus shows durable pediatric and older-adult control; Enspryng supports MOGAD attack reduction.
Late‑stage results show divarasib superiority in KRAS G12C NSCLC, giredestrant preserves quality of life while improving efficacy, and Tam‑Peli shows robust activity in nasopharyngeal carcinoma.
FDA clears the first at‑home subcutaneous IL‑6R treatment for TED; Phase III SatraGO‑2 showed marked proptosis and diplopia improvements and safety consistent with prior NMOSD data.
Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.
FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.
VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.
active all projects
